XML 34 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration Agreements - Additional Information (Detail)
 1 Months Ended 3 Months Ended 9 Months Ended 29 Months Ended
Apr. 02, 2018
May 05, 2016
Apr. 30, 2018
USD ($)
Target
$ / shares
shares
Feb. 28, 2018
USD ($)
May 31, 2016
USD ($)
Program
$ / shares
shares
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration and license agreement, deferred revenue current           $ 103,229,000   $ 103,229,000   $ 103,229,000 $ 1,275,000
Proceeds from issuance of ordinary shares, net of offering costs               60,000,000 $ 93,509,000    
Collaboration revenue recognized           4,493,000 $ 1,315,000 $ 10,794,000 $ 2,795,000    
Pfizer Inc. [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Number of research programs, counterparty nomination | Program         5            
Research term, description               Under the Pfizer Collaboration Agreement, the parties agreed to collaborate during a four-year research term. During the research term, the Company is responsible to use its commercially reasonable efforts to advance up to five programs through to the selection of clinical candidates. At that stage, Pfizer may elect to license any of these Pfizer Programs exclusively and obtain exclusive rights to undertake the clinical development of the resulting clinical candidates into products and the potential commercialization of any such products thereafter.      
Collaboration agreement, additional period after research program         2 years            
Collaboration agreement, data package receiving period         120 days            
Up-front consideration received         $ 10,000,000            
Revenue recognized           1,000,000   $ 3,900,000   8,800,000  
Collaboration and license agreement, deferred revenue           9,700,000   9,700,000   9,700,000  
Collaboration and license agreement, deferred revenue current           6,700,000   $ 6,700,000   6,700,000  
Remaining research term               19 months      
Takeda [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Up-front consideration received     $ 110,000,000                
Research, License and Option Agreement [Member] | Pfizer Inc. [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Upfront payment under collaboration agreement         10,000,000            
Collaboration agreement refundable         $ 0            
Shares issued under equity agreement | shares         1,875,000            
Equity investment aggregate purchase price         $ 30,000,000            
Purchase price per share | $ / shares         $ 16.00            
Collaborative agreement research term         4 years            
Collaboration agreement termination period   90 days                  
Collaboration And License Agreement [Member] | Category One Programs [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Percentage of global costs and potential profits sharing ratio     50.00%                
Collaboration And License Agreement [Member] | Takeda [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Upfront payment under collaboration agreement     $ 110,000,000                
Collaboration agreement termination period 180 days                    
Collaboration and license agreement, deferred revenue           163,100,000   $ 163,100,000   163,100,000  
Collaboration and license agreement, deferred revenue current           96,600,000   96,600,000   96,600,000  
Collaboration and license agreement month and year     2018-02                
Fund receivable for research and preclinical activities     $ 60,000,000                
Research term under collaboration and license agreement     4 years                
Collaboration agreement commencement date Apr. 02, 2018                    
Collaboration revenue recognized           3,500,000   6,900,000      
Collaboration and license agreement, accounts receivable           60,000,000   60,000,000   60,000,000  
Collaboration and license agreement, accounts receivable current           $ 10,000,000   $ 10,000,000   $ 10,000,000  
Collaboration And License Agreement [Member] | Takeda [Member] | Category One Programs [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Percentage of global costs and potential profits sharing ratio     50.00%                
Collaboration And License Agreement [Member] | Takeda [Member] | Category Two Programs [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Fund receivable for research and preclinical activities     $ 60,000,000                
Research term under collaboration and license agreement     4 years                
Maximum targets for preclinical programs | Target     6                
Option to reach maximum targets for preclinical programs               any one time      
Collaboration And License Agreement [Member] | Takeda [Member] | Minimum [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration agreement, committed cash       $ 230,000,000              
Collaboration and Share Purchase Agreements [Member] | Takeda [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Shares issued under equity agreement | shares     1,096,892                
Purchase price per share | $ / shares     $ 54.70                
Proceeds from issuance of ordinary shares, net of offering costs     $ 60,000,000                
Equity investment agreement official closure month and year     2018-04